Belgrade 2018 Meeting Highlights Registration Abstract Submission Exhibition Virtual Exhibition Hotel Information Satellite Programme Visa Letter Application


Search Abstracts by author or title
(results will display both Free Papers & Poster)

Precizon toric IOL in challenging cases

Poster Details

First Author: M.Dvali GEORGIA

Co Author(s): N. Tsintsadze   B. Sirbiladze   L. Jorjikashvili              

Abstract Details


To share with the experience of using Precizon Toric IOL (Ophtec) in unordinary cases of cataract surgery. Many cataract patients are with conditions that preclude them from receiving toric IOLs at first glance. In regular cases the success rate of Toric IOLs is very well known. Our purpose was to show that in challenging cases implantation of Precizon Toric IOLs resulted in high functional results.


Tbilisi State Medical University, Eye clinic 'Akhali Mzera'


Retrospective study of 4 patients (6 eyes) aged from 42 to 67 years was performed. The 1 of them was with previous PK, one eye with non-progressive KC, the 4 others - with extremely high myopia or hyperopia and astigmatism. Axial lengths ranged from 21 to 30 mm, and keratometry readings from 40.0 D to 47.0 D, astigmatism from 3.5 D to 7.5 D. All the eyes were implanted with Precizon Toric IOL. SE of implanted IOL was calculated using SRK/T, Holladay, SRK II or Haigis formulas according the length of the eyes.


Postoperative visual acuity uncorrected was 20/20 in all 6 cases with near-plano refractive results. Configuration of Haptics of Precizon Toric IOL provided the stabile position of the IOL in the capsular bag during the 12 months of follow-up period. The unique design of Precizon Toric IOL’s optical surface prevented the reduction of quality of vision even in cases of misalignment of the IOL within 5 degrees.


Precizon® Toric IOL revealed very good performance regarding predictability, efficacy, safety and IOL stability even after surgery during one year in cataract patients in unordinary cases: high myopia, hyperopia, astigmatism.

Financial Disclosure:


Back to Poster listing